Organogenesis(NASDAQ) ORGO

Market Cap$315.25M

Since IPO (2019)-81%

5 Year-84%

1 Year-47%

1 Month+1%

$2.45

-2.78%

-0.07Today

Organogenesis last closing stock price
Metric	Price	Date
Last close	USD 2.45	2026-07-30

Organogenesis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.82%	USD 2.43	2026-07-23
1 month	+0.82%	USD 2.43	2026-06-30
3 month	-4.67%	USD 2.57	2026-05-01
Year to date	-52.7%	USD 5.18	2025-12-31
1 year	-47.42%	USD 4.66	2025-07-30
3 year	-42.62%	USD 4.27	2023-07-31
5 year	-84.03%	USD 15.34	2021-07-30
Since inception	-81.25%	USD 13.44	2019-01-08

Organogenesis Financials at a Glance

Market Cap

$315.25M

Revenue (TTM)

$513.57M

Net Income (TTM)

-$284.00K

EPS (TTM)

-$0.16

P/E Ratio

-15.41

Dividend

$0.00

Beta (Volatility)

1.57 (High)

Dividend

$0.00

Beta (Volatility)

1.57 (High)

Price

$2.45

Volume

418

Open

$2.51

Price

$2.45

Volume

418

Open

$2.51

Previous Close

$2.45

Daily Range

$2.39 - $2.52

52-Week Range

$2.04 - $7.08

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.57 (High)

Price

$2.45

Volume

418

Open

$2.51

Previous Close

$2.45

Daily Range

$2.39 - $2.52

52-Week Range

$2.04 - $7.08

Estimated Earnings Date

Aug 6, 2026

ORGO News

Page 1

ORGO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Organogenesis

Organogenesis makes medical products that help people heal from serious wounds. These products use special tissues to fix skin and bone injuries. Doctors use these tools in hospitals and private medical offices.

Healing Tissues and Medical Solutions

Advanced Wound Care: Regenerative products for chronic wounds like diabetic foot ulcers; earned $29.5 million in net product revenue during Q1 2026.
Surgical and Sports Medicine: Tissues used for repairing tendons and ligaments during surgery; generated $6.8 million in net product revenue in Q1 2026.
Bioengineered Tissues: Living cell therapies such as Apligraf and Dermagraft that help the body rebuild damaged skin.
Placental Allografts: Protective wound coverings made from birth tissues, such as Affinity and NuShield, which support natural healing.

Recent Moves and Facility Plans

Partnered with Vivex Biologics, Inc. in November 2023 to sell and manufacture new wound care products.
Exercised an option in March 2024 to expand the license for VIA Matrix products with Vivex Biologics, Inc.
Leased a new biomanufacturing facility in Smithfield, Rhode Island, in November 2024 to increase production capacity.
Submitted a rolling Biologics License Application (BLA)—a request for permission to sell a biological product—for ReNu in December 2025.
Commenced a restructuring plan in March 2026 to close the St. Petersburg facility and reduce headcount by 10%.

What Sets Organogenesis Apart

The company maintains a competitive advantage through multiple products with Premarket Application (PMA) approval, which is the FDA's strictest review process for medical devices. Its specialized direct sales force provides technical expertise to hospitals and wound care centers across the United States.

The Numbers Behind the Business

Total revenue fell to $37.2 million in Q1 2026, down 57.1% from the previous year.
Net loss deepened to $56.2 million in Q1 2026, a 198% decline compared to Q1 2025.
Free cash flow turned positive at $18 million in Q1 2026, an improvement from a $23.6 million deficit a year earlier.
Operating cash flow reached $21.1 million in Q1 2026, up 206% from a $19.9 million loss in the same period of 2025.

Looking at the Big Picture

Organogenesis is transitioning its manufacturing footprint to a new Rhode Island facility while navigating significant changes in Medicare reimbursement policies. The company continues to focus on its clinical pipeline to address complex surgical and wound care needs.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

854

CEO

Gary S. Gillheeney, Sr., MBA

Website

www.organogenesis.com

Headquarters

Canton, MA 02021, US

ORGO Financials

Key Financial Metrics (TTM)

Gross Margin

70.41%

Operating Margin

2.14%

Net Income Margin

-0.06%

Return on Equity

-0.07%

Return on Capital

9.86%

Return on Assets

-0.05%

Earnings Yield

-6.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$315.25M

Shares Outstanding

128.68M

Volume

418

Avg. Volume

1.02M

Financials (TTM)

Gross Profit

$361.62M

Operating Income

$11.02M

EBITDA

$37.31M

Operating Cash Flow

$30.75M

Capital Expenditure

-$13.67M

Free Cash Flow

$17.08M

Cash & ST Invst.

$92.10M

Total Debt

$70.86M

Organogenesis Performance Analysis

Organogenesis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 450,893,000	-3.5%
2023	2023-12-31	USD 433,140,000	-3.9%
2024	2024-12-31	USD 482,043,000	11.3%
2025	2025-12-31	USD 564,169,000	17.0%

Organogenesis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	16.2%
Q3	2025-09-30	49.3%
Q4	2025-12-31	49.6%
Q1	2026-03-31	-83.5%

Organogenesis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.12	-83.4%
2023	2023-12-31	USD 0.04	-68.3%
2024	2024-12-31	USD 0.01	-82.5%
2025	2025-12-31	USD 0.15	2264.6%

Organogenesis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	43.4%
Q3	2025-09-30	214.3%
Q4	2025-12-31	145.5%
Q1	2026-03-31	-263.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$37.23M

-57.1%

Gross Profit

-$914.00K

-101.5%

Gross Margin

-2.46%

N/A

Market Cap

$315.25M

N/A

Market Cap/Employee

$369.15K

N/A

Employees

854

N/A

Net Income

-$56.16M

-198.0%

EBITDA

-$56.10M

-187.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$92.10M

-16.2%

Total Debt

$70.86M

+66.2%

Accounts Receivable

$116.91M

+13.2%

Inventory

$28.43M

-3.1%

Long Term Debt

$61.14M

+83.2%

Short Term Debt

$9.72M

+5.0%

Return on Assets

-0.05%

N/A

Return on Invested Capital

2.48%

N/A

Free Cash Flow

$17.98M

+176.3%

Operating Cash Flow

$21.13M

+206.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SNDLSNDL Inc.

SNDLSNDL Inc.$1.25+4.17%

CMPXCompass Therapeutics, Inc.

CMPXCompass Therapeutics, Inc.$1.94+0.00%

BCYCBicycle Therapeutics plc

BCYCBicycle Therapeutics plc$4.01+3.89%

EBSEmergent BioSolutions Inc.

EBSEmergent BioSolutions Inc.$7.26-1.22%

EOLSEvolus, Inc.

EOLSEvolus, Inc.$6.01-0.33%

SIGASIGA Technologies, Inc.

SIGASIGA Technologies, Inc.$3.25-2.69%

VREXVarex Imaging Corporation

VREXVarex Imaging Corporation$11.07+1.10%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$26.97+0.37%

NOKNokia

NOKNokia$9.09+0.08%

SKHYSK Hynix

SKHYSK Hynix$149.00+0.18%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.30+0.10%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.21+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$44.62-0.10%

INTCIntel

INTCIntel$91.13+0.11%

Questions About ORGO

What is the current price of Organogenesis?

Organogenesis is trading at $2.45 per share.

What is the 52-week range for Organogenesis?

Over the past 52 weeks, Organogenesis has traded between $2.04 and $7.08.

How much debt does Organogenesis have?

As of the most recent reporting period, Organogenesis reported total debt of $70.86M.

How much cash does Organogenesis have on hand?

Organogenesis reported $92.10M in cash and cash equivalents in its most recent financial results.

What is Organogenesis’s dividend yield?

Organogenesis does not currently have a dividend yield.

Organogenesis(NASDAQ) ORGO

Organogenesis Financials at a Glance

ORGO News

ORGO Sales Drop 23%

Why Organogenesis Holding Stock Plummeted by 18% Today

Why Shares of Organogenesis Holdings Are Up Thursday

Why Shares of Organogenesis Holdings Are Dropping Thursday

Why Shares of Organogenesis Climbed Wednesday

Why Shares of Organogenesis Holdings Jumped Thursday

Why Organogenesis Stock Is Tumbling Today

Is This Healthcare Stock a Value Trap?

ORGO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Organogenesis

Healing Tissues and Medical Solutions

Recent Moves and Facility Plans

What Sets Organogenesis Apart

The Numbers Behind the Business

Looking at the Big Picture

ORGO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Organogenesis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ORGO

What is the current price of Organogenesis?

What is the 52-week range for Organogenesis?

How much debt does Organogenesis have?

How much cash does Organogenesis have on hand?

What is Organogenesis’s dividend yield?

Premium Investing Services